ImClone touts increased survival rate in Erbitux cancer trial

ImClone Systems is touting results of a late-stage trial that shows patients with head and neck cancer lived an average of 19.7 months longer while taking Erbitux rather than radiation alone. Median survival for radiation-only patients was 29.3 months. ImClone has applied for expanded use of Erbitux for head and neck cancer.

- read this press release for more information